On March 26, 2015, Marcin, Lawrence R.; Higgins, Mendi A.; Bronson, Joanne J.; Zusi, F. Christopher; Macor, John E.; Ding, Min published a patent.Application In Synthesis of Methyl 2-(2,6-difluorophenyl)acetate The title of the patent was Preparation of triazolopyridine ether derivatives useful in treatment of neurological and psychiatric disorders. And the patent contained the following:
The invention relates to compounds of formula I and their preparation, as modulators of the mGluR2 receptor potentially useful for the treatment of various disorders of the central nervous system including neurol. and psychiatric disorders. Compounds of formula I are claimed, in which R1 is H, CN, halo, (halo)alkyl, etc.; R2 is (halo)alkyl, (cycloalkyl)alkyl, etc.; R3 is Ar1 and OAr1; Ar1 is (un)substituted Ph, pyridinyl, pyrimidinyl, etc.; Y is bond and (un)substituted C3-6 cycloalkyl; Z is bond and (un)substituted C1-3 alkyl; provided that when Y and Z are bonds, R3 is Ar1; or pharmaceutically acceptable salts thereof. Example compound II was prepared by cyclocondensation of 2-hydrazinyl-4-((1-phenylcyclohexyl)methoxy)-3-(trifluoromethyl)pyridine with 2-cyclopropylacetyl chloride to afford 2-cyclopropyl-N’-(4-((1-phenylcyclohexyl)methoxy)-3-(trifluoromethyl)pyridin-2-yl)acetohydrazide, which underwent cyclization with Burgess reagent to yield II. Invention compounds were evaluated for their human mGluR2 inhibitory activity. From the assay, it was determined that II exhibited EC50 value of 1.8 nM. The experimental process involved the reaction of Methyl 2-(2,6-difluorophenyl)acetate(cas: 872046-08-7).Application In Synthesis of Methyl 2-(2,6-difluorophenyl)acetate
The Article related to triazolopyridine ether preparation treatment cns neurol psychiatric disorder, Heterocyclic Compounds (More Than One Hetero Atom): Other 6-Membered Rings, Three Or More Hetero Atoms and other aspects.Application In Synthesis of Methyl 2-(2,6-difluorophenyl)acetate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics